Navigation Links
Align Technology Announces Second Quarter Fiscal 2008 Results

- Record Q2 net revenues of $79.9 million increase 6.9 percent sequentially

- Q2 GAAP net profit of $4.0 million, or $0.06 per diluted share

- Case shipments of 54,870 increase 6.0 percent sequentially

- Initiating cost-saving measures including a workforce reduction

SANTA CLARA, Calif., July 29 /PRNewswire-FirstCall/ -- Align Technology, Inc. (Nasdaq: ALGN) today reported financial results for the second quarter of fiscal 2008, ended June 30, 2008.

Total net revenues for the second quarter of fiscal 2008 (Q2 08) were a record $79.9 million. This reflects a year-over-year increase of 4.3 percent compared to $76.6 million in the second quarter of 2007 (Q2 07). On a sequential basis, net revenues increased 6.9 percent from $74.8 million in the first quarter of 2008 (Q1 08). Q2 07 shipments included approximately four thousand cases and revenue of $5.2 million from the reduction in backlog and cycle times caused by the allocation of capacity to the Patients First Program during the fourth quarter of 2006 and the first quarter of 2007.

"I'm pleased with our solid performance in the second quarter despite an ever more challenging economic environment for our doctors and their patients," said Thomas M. Prescott, president and CEO of Align Technology. "During the second quarter, we continued to execute on our strategic initiatives including today's launch of Invisalign Teen following the successful pilot of the product."

Net profit for Q2 08 was $4.0 million, or $0.06 per diluted share. This is compared to net profit of $13.6 million, or $0.19 per diluted share in Q2 07, and net profit of $5.3 million, or $0.07 per diluted share in Q1 08. Stock-based compensation expense included in Q2 08 net profRATIONS

(in thousands, except per share data)

Three Months Ended Six Months Ended

June 30, June 30, June 30, June 30,

2008 2007 2008 2007

Net revenues $79,902 $76,603 $154,678 $140,364

Cost of revenues 20,243 20,247 39,851 37,776

Gross profit 59,659 56,356 114,827 102,588

Operating expenses:

Sales and marketing 32,464 24,353 60,523 47,503

General and administrative 16,322 11,880 31,510 24,065

Research and development 7,001 6,675 14,296 12,368

Patients First Program - - - (1,796)

Total operating expenses 55,787 42,908 106,329 82,140

Profit from operations 3,872 13,448 8,498 20,448

Interest and other income, net 443 680 1,409 1,135

Profit before income taxes 4,315 14,128 9,907 21,583

Provision for income taxes (285) (510) (573) (987)

Net profit $4,030 $13,618 $9,334 $20,596

Net profit per share

- basic $0.06 $0.20 $0.14 $0.31

- diluted $0.06 $0.19 $0.13 $0.29

Shares used in computing net profit

per share

- basic 68,581 66,696 68,817 66,068

- diluted 69,916 71,207 70,478 70,346



(in thousands)

June 30, 2008 December 31, 2007


Current assets:

Cash and cash equivalents $64,339 $89,140

Marketable securities, short-term 45,723 38,771

Accounts receivable, net 51,173 44,850

Inventories, net 3,017 2,910

Other current assets 10,132 8,846

Total current assets 174,384 184,517

Property and equipment, net 29,525 25,320

Goodwill and intangible assets, net 9,675 11,093

Other long-term assets 3,585 1,831

Total assets $217,169 $222,761


Current liabilities:

Accounts payable $8,965 $9,222

Accrued liabilities 34,708 39,875

Deferred revenues 14,144 12,362

Total current liabilities 57,817 61,459

Other long term liabilities 133 148

Total liabilities 57,950 61,607

Total stockholders' equity 159,219 161,154

Total liabilities and stockholders'

equity $217,169 $222,761




The outlook figures provided below and elsewhere in this press release are approximate in nature since Align's business outlook is difficult to predict. Align's future performance involves numerous risks and uncertainties and the company's results could differ materially from the outlook provided. Some of the factors that could affect Align's future financial performance and business outlook are set forth under "Forward-Looking Information" above in this press release. This outlook excludes the effects of any stock repurchases.

Financials (including reconciliation of GAAP to non-GAAP financial


(in millions, except per share amounts and percentages)

Q3 2008

GAAP Adjustment(a) Non-GAAP

Net Revenue $74.0 - $76.0 $74.0 - $76.0

Gross Margin 73.6% - 74.4% 73.6% - 74.4%

Operating Expenses $53.7 - $55.2 $2.2(a) $51.5 - $53.0

Net Profit % 1% - 2% 3% 4% - 5%

Net Profit per Diluted

Share $0.01 - $0.03 $0.03 $0.04 - $0.06

Stock Based Compensation


Cost of Revenues $0.4 $0.4

Operating Expenses $4.3 $4.3

Total Stock Based

Compensation Expense $4.7 $4.7

(a) Restructuring charges

Business Metrics:

Q3 2008

Case Shipments 51.0K - 53.0K

Cash $116M - $120M

DSO ~57 days

Capex $3.0M - $5.0M

Depreciation &

Amortization $2.0M - $3.0M

Diluted Shares

Outstanding 70.0M

FY 2008

FY 2008 Adjustment(a) Non-GAAP

Net Revenue $309.0 - $314.0 $309.0 - $314.0

Gross Margin 73.7% - 74.2% 73.7% - 74.2%

Operating Expenses $210.8 - $213.8 $2.6(a) $208.2 - $211.2

Net Profit % 6% - 7% 1% 7% - 8%

Net Profit per Diluted

Share $0.26 - $0.30 $0.03 $0.29 - $0.33

Stock Based Compensation


Cost of Revenues $1.7 $1.7

Operating Expenses $16.2 $16.2

Total Stock Based

Compensation Expense $17.9 $17.9

Increase in Deferred

Revenue $5.0 - $8.0 $5.0 - $8.0

Total Deferred Revenue

Balance $17.0 - $20.0 $17.0 - $20.0

(a) Restructuring charges

Business Metrics:

FY 2008

Case Shipments 213.0K - 216.5K

Cash $130M - $135M

DSO ~57 days

Capex $14.0M - $18.0M

Depreciation &

Amortization $13.0M - $14.0M

Diluted Shares

Outstanding 70.0M

it was $4.8 million, compared to $2.9 million in Q2 07, and $4.0 million in Q1 08.

The Company also announced measures to reduce operating expenses.

Prescott said, "As consumer spending has continued to soften, so has our outlook for revenue growth. As a result, we're reducing overall company spending and slowing headcount growth while preserving the important investments in strategic priorities. Unfortunately, valued employees will be affected, and those are decisions that the management team and I do not take lightly. These actions are only the first steps in actively reducing our cost structure and moving towards a financial model with greater operating leverage."

The cost-saving measures include: a reduction in full time headcount of 38, slowing headcount growth for the remainder of 2008, and cuts in discretionary spending. These actions will reduce expenses in the second half of 2008 by approximately $5 million to $6 million. In addition, the company is implementing a phased consolidation of its order acquisition operations in Santa Clara, California into its existing operations in Juarez, Mexico by the end of 2008. Upon completion, 29 positions in Santa Clara will be eliminated, resulting in annualized cost savings of approximately $1.0 to $1.5 million in 2009. As part of these actions, Align will record a restructuring charge estimated to be approximately $2.6 million in the second half of fiscal 2008, of which approximately $2.2 million will be realized in Q3 08. At the end of Q2 08, Align had a regular employee base of approximately 1,400 worldwide.

Q2 08 Operating Results

Key GAAP Operating Results Q2 08 Q1 08 Q2 07

Gross Margin 74.7% 73.8% 73.6%

Operating Expense $55.8M $50.5M $42.9M

Operating Margin 4.8% 6.2% 17.6%

Net Profit $4.0M $5.3M $13.6M

Earnings Per Diluted Share (EPS) $0.06 $0.07 $0.19

Liquidity and Capital Resources

As of June 30, 2008, Align had $110.1 million in cash, cash equivalents, and short term marketable securities compared to $127.9 million as of December 31, 2007. During Q2 08, Align purchased 2.2 million shares at an average price of $12.65 per share for a total of $27.7 million. There remains $22.3 million under the Company's existing stock repurchase authorization.

Key Business Metrics

The following table highlights business metrics for Align's second quarter of 2008. Additional historical information is available on the Company's website at

Revenue by Channel: Q2 08 Q2'08/Q1'08 Q2'08/Q2'07

% Change % Change (a)

U.S. Orthodontists $23.3M 2.1% (6.7%)

U.S. GP Dentists $36.6M 5.2% 0.6%

International $16.4M 15.8% 41.3%

Training and Other $3.6M 20.2% (1.1%)

Total Revenue $79.9M 6.9% 4.3%

Average Selling Price (ASP): Q2 08 Q2'08/Q1'08 Q2'08/Q2'07

% Change % Change

Total Worldwide Blended ASP $1,390 0.7% 4.5%

Total Worldwide ASP excluding

Invisalign Express $1,500 (0.7%) 4.9%

U.S. Orthodontists Blended ASP $1,290 (0.8%) 4.9%

U.S. GP Dentists Blended ASP $1,340 0.0% 2.3%

International $1,700 0.0% 4.3%

Number of Cases Shipped: Q2 08 Q2'08/Q1'08 Q2'08/Q2'07

% Change % Change (a)

U.S. Orthodontists -- Full

Invisalign 14,830 2.3% (11.9%)

U.S. Orthodontists --

Invisalign Express 3,250 5.2% (3.6%)

U.S. GP Dentists -- Full

Invisalign 22,140 5.9% (2.7%)

U.S. GP Dentists --

Invisalign Express 4,970 0.4% 1.2%

International -- Full

Invisalign 9,520 16.1% 35.4%

International --

Invisalign Express 160 23.1% 45.5%

Total Cases Shipped 54,870 6.0% (0.3%)

Number of Doctors Cases

were Shipped to: Q2 08

U.S. Orthodontists 3,730

U.S. GP Dentists 11,030

International 2,910

Total Doctors Cases were

Shipped to Worldwide 17,670

Number of Doctors Trained

Worldwide: Q2 08 Cumulative

U.S. Orthodontists 100 8,510

U.S. GP Dentists 1,630 30,260

International 600 13,340

Total Doctors Trained Worldwide 2,330 52,110

Multiple Case Doctors

(Cumulative as of): Q2 08

U.S. Orthodontists 90.5%

U.S. GP Dentists 86.6%

International 77.2%

Doctors Starting Invisalign

Treatment (Cumulative as of): Q2 08

U.S. Orthodontists 6,920

U.S. GP Dentists 23,820

International 7,390

Total Doctors Starting

Invisalign Treatment 38,130

Doctor Utilization Rates*: Q2 08 Q1 08 Q2 07(a)

U.S. Orthodontists 4.9 4.8 5.3

U.S. GP Dentists 2.5 2.4 2.7

International 3.3 3.2 3.1

Total Utilization Rate 3.1 3.1 3.4

* Utilization = # of cases/# of doctors to whom cases were shipped

(a) Q2 07 shipments included approximately four thousand cases and revenue

of $5.2 million from the reduction in backlog and cycle times caused

by the allocation of capacity to the Patients First Program during the

fourth quarter of 2006 and the first quarter of 2007

Business Outlook

For the third quarter of fiscal 2008 (Q3 08), Align Technology expects net revenues to be in a range of $74 million to $76 million. GAAP earnings per diluted share for Q3 08 is expected to be in a range of $0.01 to $0.03. Non-GAAP earnings per diluted share for Q3 08 is expected to be in a range of $0.04 to $0.06. Stock-based stock compensation expense for Q3 08 is expected to be approximately $4.7 million.

For fiscal 2008, Align Technology expects net revenues to be in a range of $309 million to $314 million. The increase in deferred revenue for fiscal 2008 is expected to be in the range of $5 million to $8 million primarily associated with new products, which will be recognized in future periods, bringing the Company's total deferred revenue balance at the end of 2008 to a range of $17 million to $20 million. GAAP earnings per diluted share for fiscal 2008 is expected to be in a range of $0.26 to $0.30. Non-GAAP earnings per diluted share for fiscal 2008 is expected to be in a range of $0.29 to $0.33. Stock-based compensation expense for fiscal 2008 is expected to be approximately $17.9 million.

A more comprehensive business outlook is available following the financial tables of this release.

Invisalign Teen

In a separate announcement today Align also announced a new addition to its Invisalign product family: Invisalign Teen for non-adult, comprehensive orthodontic treatment. For more information, please see Align's press release titled, " Align Technology Targets Mainstream Orthodontics Market with Invisalign Teen."

Align Web Cast and Conference Call

Align Technology will host a conference call today, July 29, 2008 at 4:30 p.m. ET, 1:30 p.m. PT, to review its second quarter fiscal 2008 results, discuss future operating trends and business outlook. The conference call will also be web cast live via the Internet. To access the web cast, go to the "Events & Presentations" section under Company Information on Align Technology's Investor Relations web site at To access the conference call, please dial 201-689-8341 approximately fifteen minutes prior to the start of the call. If you are unable to listen to the call, an archived web cast will be available beginning approximately one hour after the call's conclusion and will remain available for approximately 12 months. Additionally, a telephonic replay of the call can be accessed by dialing 877-660-6853 with account number 292 followed by # and conference number 289687 followed by #. The replay must be accessed from international locations by dialing 201-612-7415 and using the same account and conference numbers referenced above. The telephonic replay will be available through 4:30 p.m. ET on August 12, 2008.

About Align Technology, Inc.

Align Technology designs, manufactures and markets Invisalign, a proprietary method for treating malocclusion, or the misalignment of teeth. Invisalign corrects malocclusion using a series of clear, nearly invisible, removable appliances that gently move teeth to a desired final position. Because it does not rely on the use of metal or ceramic brackets and wires, Invisalign significantly reduces the aesthetic and other limitations associated with braces. Invisalign is appropriate for treating adults and older teens. Align Technology was founded in March 1997 and received FDA clearance to market Invisalign in 1998.

To learn more about Invisalign or to find a certified Invisalign doctor in your area, please visit or call 1-800-INVISIBLE.

About non-GAAP Financial Measures

To supplement our business outlook, we use the following non-GAAP financial measures: non-GAAP operating expenses, net profit (loss), earnings (loss) per share, which excludes the restructuring charge. The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. For more information on these non-GAAP financial measures, please see the tables captioned "Business Outlook Summary" included at the end of this release.

We use these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our "core operating performance". Management believes that "core operating performance" represents Align's performance in the ordinary, ongoing and customary course of its operations. Accordingly, management excludes from "core operating performance" certain expenses and expenditures that may not be indicative of our operating performance including discrete cash charges that are infrequent or one-time in nature. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management's internal evaluation of period-to-period comparisons. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision making and (2) they are provided to and used by our institutional investors and the analyst community to facilitate comparisons with prior and subsequent reporting periods.

Forward-Looking Statement

This news release, including the tables below, contains forward-looking statements, including statements regarding Align's anticipated amount of cost savings due to the cost-saving measures, the expected amount of and timing of the charges to be incurred in connection with these measures and Align's anticipated financial results and certain business metrics for the third quarter and full year of 2008, including anticipated revenue and deferred revenue, gross profit, gross margin, operating expense, net profit, earnings per share, percentage of revenue by channel, case shipments and average selling prices. Forward-looking statements contained in this news release and the tables below relating to expectations about future events or results are based upon information available to Align as of the date hereof. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. As a result, actual results may differ materially and adversely from those expressed in any forward-looking statement. Factors that might cause such a difference include, but are not limited to, failure to achieve the expected cost savings, including a delay in the implementation of the relocation of order acquisition to Mexico and greater than anticipated costs resulting from the relocation, changes in the size of the expected restructuring charge, the possibility that the development and release of new products does not proceed in accordance with the anticipated timeline, the possibility that the market for the sale of these new products may not develop as expected, the risks relating to Align's ability to sustain or increase profitability or revenue growth in future periods while controlling expenses, continued customer demand for Invisalign and new products, changes in consumer spending habits as a result of, among other tings, prevailing economic conditions, levels of employment, salaries and wages and consumer confidence, the timing of case submissions from our doctors within a quarter, acceptance of Invisalign by consumers and dental professionals, Align's third party manufacturing processes and personnel, foreign operational, political and other risks relating to Align's international manufacturing operations, Align's ability to protect its intellectual property rights, competition from manufacturers of traditional braces and new competitors, Align's ability to develop and successfully introduce new products and product enhancements, and the loss of key personnel. These and other risks are detailed from time to time in Align's periodic reports filed with the Securities and Exchange Commission, including, but not limited to, its Annual Report on Form 10-K for the fiscal year ended December 31, 2007, which was filed with the Securities and Exchange Commission on February 26, 2008. Align undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Investor Relations Contact Press Contact

Shirley Stacy Shannon Mangum Henderson

Align Technology, Inc. Ethos Communication, Inc.

(408) 470-1150 (678) 540-9222



SOURCE Align Technology, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Align Technology Executive to Present at Upcoming Financial Conferences
2. WellPoint Announces Realignment of Core Businesses; Names New Executives
3. Align Technology to Announce Third Quarter 2007 Financial Results on October 24, 2007
4. Align Technology, Inc. Earns PACE Approval From Academy of General Dentistry
5. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
6. Threshold Pharmaceuticals Announces Corporate Realignment
7. Early Results of Phase 2 Trial of Perifosine (KRX-0401) for the Treatment of Recurrent Malignant Gliomas Presented at the 12th Annual Scientific Meeting of Society for Neuro-Oncology
8. Dallas Among the First to Offer Probiotic Supplement Align(R)
9. McGill researchers link enzyme to breast cancer malignancy
10. Breast Cancer Genes Also Raise Mens Risk for Malignancy
11. iNOS expression may links chronic biliary inflammation to malignant transformation
Post Your Comments:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... , ... October 12, 2017 , ... HMP , ... recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ ... on October 11, 2017. , The annual award competition recognizes editorial and design excellence ...
(Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers were ... innovative way to use nonlinear optical imaging to confirm ... drugs. A ... show how researchers from BioPharmX and the Wellman Center ... a suite of imaging techniques in what is called ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
Breaking Medicine Technology: